Managing Jaundice Neonatal

Managing Jaundice Neonatal

Applies the AAP 2022 Clinical Practice Guideline for the Management of Hyperbilirubinemia in the Newborn Infant ≥ 35 Weeks' Gestation. Structures bilirubin risk assessment using the Bhutani hour-specific nomogram, determines phototherapy and exchange transfusion thresholds based on neurotoxicity risk factors, and guides safe discharge planning with follow-up scheduling.

Why This Skill Exists

Neonatal hyperbilirubinemia affects approximately 60% of term and 80% of preterm newborns. While most jaundice is physiologic, failure to identify and treat pathologic hyperbilirubinemia can result in acute bilirubin encephalopathy (ABE) and chronic bilirubin encephalopathy (kernicterus) — an entirely preventable form of brain damage. The AAP 2022 guideline (replacing the 2004 guideline) provides updated, hour-specific phototherapy and exchange transfusion thresholds with explicit neurotoxicity risk factor assessment. This skill enforces the updated protocol.

Checkpoint A — Intake Verification

Required Intake Questions

1. What is the infant's gestational age (this guideline applies to ≥ 35 weeks)?
2. What is the infant's age in hours (critical for nomogram plotting)?
3. What is the maternal and infant blood type and direct Coombs (DAT) result?
4. What is the current bilirubin level — total serum bilirubin (TSB) or transcutaneous bilirubin (TcB)?
5. Is the infant breastfeeding? How is feeding going (latch, frequency, urine/stool output)?
6. What is the infant's current weight and percent weight loss from birth weight?
7. Are there any neurotoxicity risk factors present (see Step 2)?
8. Has the infant had a prior bilirubin measurement? If so, what was the rate of rise?

Required Documents

• Maternal blood type and antibody screen
• Infant blood type and direct antiglobulin test (DAT/Coombs)
• Serial bilirubin measurements with time stamps (TSB or TcB)
• Birth weight and current weight
• Feeding log (type of feeding, frequency, output)
• G6PD status (if known or if high-risk ethnicity)

TcB is acceptable for screening but if TcB is within 3 mg/dL of the phototherapy threshold, a confirmatory TSB must be obtained.

Step 1 — Bilirubin Measurement and Risk Zone Assignment (Bhutani Nomogram)

Pre-Discharge Bilirubin Assessment

• Obtain TSB or TcB on every newborn before discharge (universal screening per AAP 2022)
• Plot the result on the Bhutani hour-specific bilirubin nomogram
• Assign risk zone:

Rate of Rise

• Calculate bilirubin rate of rise if ≥ 2 values available
• Rate > 0.2 mg/dL/hour in first 24 hours is concerning for hemolysis
• Rate > 0.3 mg/dL/hour at any time warrants urgent evaluation

First 24 Hours

• Jaundice visible in the first 24 hours of life is ALWAYS pathologic until proven otherwise
• Obtain TSB immediately and evaluate for hemolytic disease (blood type incompatibility, G6PD deficiency, spherocytosis)

Step 2 — Neurotoxicity Risk Factor Assessment

The AAP 2022 guideline uses neurotoxicity risk factors to adjust phototherapy and exchange transfusion thresholds. Identify the presence of ANY of the following:

Neurotoxicity Hyperbilirubinemia Risk Factors

• Gestational age 35-37 weeks and 6 days (lower GA = higher risk)
• Albumin < 3.0 g/dL
• Isoimmune hemolytic disease (positive DAT — ABO or Rh incompatibility)
• G6PD deficiency
• Significant lethargy or sepsis
• Acidosis (pH < 7.15)
• Instability of clinical condition

Risk Category Assignment

Step 3 — Phototherapy Initiation

AAP 2022 Phototherapy Thresholds (Hour-Specific)

Thresholds vary by infant age in hours and risk category. Key representative values for term infants without risk factors:

Use the actual AAP 2022 phototherapy nomogram for precise thresholds at each hour of life — the above are approximate reference points.

Phototherapy Technical Standards

• Intensive phototherapy delivers ≥ 30 µW/cm²/nm in the 430-490 nm wavelength band
• Maximize skin surface area exposure (diaper only, no eye shields blocking forehead)
• Proper eye protection (opaque eye shields, check position frequently)
• Continue breastfeeding during phototherapy (supplement if intake is inadequate)
• Recheck TSB 4-6 hours after initiation; then every 6-12 hours during treatment
• Do NOT use sunlight exposure as a substitute for phototherapy

When to Escalate

• TSB rising despite phototherapy → verify equipment irradiance, increase skin exposure, consider double or triple lights
• TSB approaching exchange transfusion threshold → prepare for potential exchange; notify NICU/transport

Step 4 — Exchange Transfusion Thresholds

Indications for Exchange Transfusion

• TSB exceeds exchange transfusion threshold for age in hours and risk category (approximately 5 mg/dL above phototherapy threshold in most cases)
• TSB fails to decline by 1-2 mg/dL within 4-6 hours of intensive phototherapy and is approaching exchange threshold
• Signs of acute bilirubin encephalopathy (ABE) at ANY bilirubin level

Signs of Acute Bilirubin Encephalopathy (ABE)

Early phase:

• Lethargy, hypotonia, poor suck Advanced phase:
• Hypertonia (retrocollis, opisthotonos), high-pitched cry, fever
• Any neurologic sign attributable to bilirubin → EMERGENT exchange transfusion regardless of TSB level

Exchange Transfusion Protocol

• Double-volume exchange (160-180 mL/kg) replaces approximately 85% of circulating RBCs
• Reduces TSB by approximately 50%
• Requires NICU setting with continuous monitoring
• Complications: electrolyte disturbances (hypocalcemia, hyperkalemia), thrombocytopenia, NEC, line complications, cardiac arrhythmia

Step 5 — Discharge Planning and Follow-Up

Pre-Discharge Checklist

• Pre-discharge TSB or TcB plotted on Bhutani nomogram with risk zone assigned
• Risk factors documented (blood type, DAT, G6PD if applicable, GA)
• Feeding assessment: latch, frequency, urine/stool output, percent weight loss

Follow-Up Scheduling Based on Risk Zone and Age at Discharge

Phototherapy Discontinuation

• Discontinue when TSB drops 2-3 mg/dL below the phototherapy threshold for age
• Recheck TSB 12-24 hours after discontinuation (rebound occurs in ~10-15% of cases)
• Higher rebound risk with hemolytic disease and younger gestational age

Breastfeeding Support

• Do NOT discontinue breastfeeding for jaundice management
• Optimize breastfeeding: 8-12 feeds/day, lactation consultation, supplement with expressed breast milk or formula if intake is insufficient
• "Breastfeeding jaundice" (suboptimal intake) is managed by improving breastfeeding, not stopping it
• "Breast milk jaundice" (prolonged indirect hyperbilirubinemia after 1 week) rarely requires intervention; TSB > 20 mg/dL warrants evaluation but does not typically require cessation of breastfeeding

Checkpoint B — Jaundice Management Review

• TSB or TcB obtained with exact time stamp and infant age in hours
• Bilirubin plotted on Bhutani nomogram with risk zone documented
• Rate of rise calculated (if ≥ 2 values available)
• Neurotoxicity risk factors systematically assessed and documented
• Phototherapy threshold correctly identified for age and risk category
• If phototherapy initiated: irradiance verified, recheck interval set
• Exchange transfusion threshold identified; team aware if TSB approaching
• ABE signs assessed and documented (lethargy, tone, cry, feeding)
• Breastfeeding status assessed with plan for optimization
• Discharge follow-up scheduled per risk zone
• All [VERIFY] flags resolved or escalated

Quality Audit

Guidelines

• Follow AAP 2022 Clinical Practice Guideline for Management of Hyperbilirubinemia in Newborns ≥ 35 Weeks' Gestation (replaces 2004 guideline)
• Use Bhutani hour-specific bilirubin nomogram for pre-discharge risk stratification
• Use AAP 2022 hour-specific phototherapy and exchange transfusion threshold nomograms (separate from Bhutani prediction nomogram)
• G6PD deficiency: AAP recommends universal G6PD screening; if not available, screen high-risk populations (African, Mediterranean, Middle Eastern, Southeast Asian descent)
• TcB is valid for screening but confirm with TSB when within 3 mg/dL of threshold
• Phototherapy irradiance standard: ≥ 30 µW/cm²/nm (intensive) measured at infant skin level
• Do not interrupt breastfeeding for jaundice management — optimize feeding support
• ABE signs mandate emergent exchange transfusion at any TSB level
• Follow AAP safe discharge guidelines: no newborn should be discharged without a bilirubin assessment and follow-up plan
• This skill produces clinical documentation; it does not replace clinical judgment